Name: NOVARTIS AG-SPONSORED ADR (NVS) Stock
Brand: NOVARTIS AG-SPONSORED ADR
Rating: 8.5 (3 reviews)

NVS Latest News, Press Relases and Analysis

All

Press Releases

11 days ago - By: Chartmill

NOVARTIS AG-SPONSORED ADR (NYSE:NVS): A Comprehensive Value Investment Analysis

18 days ago - By: Chartmill

Novartis AG-Sponsored ADR (NYSE:NVS) Presents a Strong Case for Dividend Investors

2 days ago - By: Zacks Investment Research

Here's Why Novartis (NVS) is a Strong Value Stock

2 days ago - By: CNBC - Mentions: NVDA ORCL AAPL AVGO ...

Here are Wednesday's biggest analyst calls: Nvidia, Oracle, Apple, Broadcom, ASML, Marvell, Ralph Lauren & more

3 days ago - By: Stocktwits - Mentions: JANX BAC

Janux Therapeutics Stock Sinks 50% After Prostate Cancer Trial Triggers Target Cuts Across Wall Street — Retail Sees A FOMO-Fueled Rebound

6 days ago - By: The Motley Fool - Mentions: VEU BABA SAP HSBC

1 No-Brainer International Vanguard ETF to Buy Right Now for Less Than $100

6 days ago - By: The Motley Fool - Mentions: SCHD VYMI SCHW HSBC

2 High-Yielding ETFs That Can Bankroll Your Retirement for Years

8 days ago - By: Zacks Investment Research

Here's Why Novartis (NVS) is a Strong Momentum Stock

10 days ago - By: Zacks Investment Research - Mentions: FOLD RNA

FDA Greenlights Novartis' Gene Replacement Treatment for SMA

10 days ago - By: Benzinga

FDA OKs Novartis SMA Treatment As First Gene Therapy Option For Kids, Teens And Adults

10 days ago - By: CNBC - Mentions: NVDA AAPL TSLA MSFT ...

Here are Tuesday's biggest analyst calls: Nvidia, Apple, Tesla, Microsoft, Oracle, Live Nation, Coinbase & more

10 days ago - By: Stocktwits

Novartis Stock Rises Premarket After FDA Approves First Gene Therapy For Teens And Adults With Muscle-Weakening Disorder

14 days ago - By: Zacks Investment Research - Mentions: FOLD RNA

NVS Ups Sales Projections as Key Drugs and Collaborations Fuel Growth

15 days ago - By: BioMedWire - Mentions: OTLC IOBT BCAX PFE

Remeasuring Biotech Pipelines: The Valuation Signal Investors Have Been Waiting For

15 days ago - By: CNBC

Novartis targets 5%-6% annual sales growth until 2030 on key cancer drugs

15 days ago - By: Stocktwits

Novartis Stock Softens Premarket Even As It Raises 2030 Outlook, Sales Guidance For Two Key Cancer Drugs

15 days ago - By: Bloomberg

Novartis Raises Peak Sales Targets for Key Cancer Drugs

15 days ago - By: Stocktwits - Mentions: UNH MRK BMY

Big Pharma Layoff Wave Extends Into Next Year: UNH, Merck, BMS, Novartis File New WARN Notices

17 days ago - By: Benzinga

Is the Market Bullish or Bearish on Novartis AG?

21 days ago - By: Zacks Investment Research

Here's Why Novartis (NVS) is a Strong Value Stock

22 days ago - By: Zacks Investment Research - Mentions: ANIP ADMA ARQT

Novartis' Phase III Malaria Study Meets Key Non-Inferiority Endpoint

23 days ago - By: Bloomberg

NOVARTIS AG-SPONSORED ADR (NVS) Stock News

NVS Latest News, Press Relases and Analysis

NOVARTIS AG-SPONSORED ADR (NYSE:NVS): A Comprehensive Value Investment Analysis

Novartis AG-Sponsored ADR (NYSE:NVS) Presents a Strong Case for Dividend Investors

Here's Why Novartis (NVS) is a Strong Value Stock

Here are Wednesday's biggest analyst calls: Nvidia, Oracle, Apple, Broadcom, ASML, Marvell, Ralph Lauren & more

Janux Therapeutics Stock Sinks 50% After Prostate Cancer Trial Triggers Target Cuts Across Wall Street — Retail Sees A FOMO-Fueled Rebound

1 No-Brainer International Vanguard ETF to Buy Right Now for Less Than $100

2 High-Yielding ETFs That Can Bankroll Your Retirement for Years

Here's Why Novartis (NVS) is a Strong Momentum Stock

FDA Greenlights Novartis' Gene Replacement Treatment for SMA

FDA OKs Novartis SMA Treatment As First Gene Therapy Option For Kids, Teens And Adults

Here are Tuesday's biggest analyst calls: Nvidia, Apple, Tesla, Microsoft, Oracle, Live Nation, Coinbase & more

Novartis Stock Rises Premarket After FDA Approves First Gene Therapy For Teens And Adults With Muscle-Weakening Disorder

NVS Ups Sales Projections as Key Drugs and Collaborations Fuel Growth

Remeasuring Biotech Pipelines: The Valuation Signal Investors Have Been Waiting For

Novartis targets 5%-6% annual sales growth until 2030 on key cancer drugs

Novartis Stock Softens Premarket Even As It Raises 2030 Outlook, Sales Guidance For Two Key Cancer Drugs

Novartis Raises Peak Sales Targets for Key Cancer Drugs

Big Pharma Layoff Wave Extends Into Next Year: UNH, Merck, BMS, Novartis File New WARN Notices

Is the Market Bullish or Bearish on Novartis AG?

Here's Why Novartis (NVS) is a Strong Value Stock

Novartis' Phase III Malaria Study Meets Key Non-Inferiority Endpoint

Novartis Malaria Drug Works Against Resistant Strains in Trial